Alzheimer’s disease (AD) is characterized by amyloid-β (Aβ)-induced phosphorylation of the axon-stabilizing tau protein, which causes neurodegeneration. Here, Morshed et al. show that deregulated phosphorylation in AD also affects other proteins and cell types in the brain, suggesting that the tau-centric view on Aβ toxicity should be revised.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Plasma extracellular vesicles reveal early molecular differences in amyloid positive patients with early-onset mild cognitive impairment
Journal of Nanobiotechnology Open Access 14 February 2023
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Johnson, E. C. B. et al. Nat. Med. 26, 769–780 (2020).
Wesseling, H. et al. Cell 183, 1699–1713 (2020).
Morshed, N. et al. Nat. Aging https://doi.org/10.1038/s43587-021-00071-1 (2021).
Wu, J., Bie, B., Foss, J. F. & Naguib, M. Mol. Neurobiol. 57, 2290–2300 (2020).
Dujardin, S., Colin, M. & Buee, L. Neuropathol. Appl. Neurobiol. 41, 59–80 (2015).
De Strooper, B. & Karran, E. Cell 164, 603–615 (2016).
Acknowledgements
Work in the authors’ laboratories is supported by the Swedish Research Council, the European Research Council, Swedish State Support for Clinical Research (ALFGBG), the Knut and Alice Wallenberg Foundation, and UK Dementia Research Institute at UCL. H.Z. is a Wallenberg Scholar.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
H.Z. has served at scientific advisory boards for Alector, Eisai, Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics, Nervgen, AZTherapies and CogRx; has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure and Biogen; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside of submitted work). G.B. declares no competing interests.
Rights and permissions
About this article
Cite this article
Brinkmalm, G., Zetterberg, H. The phosphorylation cascade hypothesis of Alzheimer’s disease. Nat Aging 1, 498–499 (2021). https://doi.org/10.1038/s43587-021-00077-9
Published:
Issue Date:
DOI: https://doi.org/10.1038/s43587-021-00077-9
This article is cited by
-
Plasma extracellular vesicles reveal early molecular differences in amyloid positive patients with early-onset mild cognitive impairment
Journal of Nanobiotechnology (2023)